Impact of genetic polymorphism of ABCB1 (MDR1) 2677G> T –A in kidney donors on tacrolimuslevel in Jordanian kidney transplant recipients during the early post transplantation period

The aim of this study was to determine the role of donors’ ABCB1 G2677T/A polymorphism ontacrolimus dose requirements, trough levels and dose-adjusted trough concentrations among Jordanianrenal transplant recipients during the early, unstable period post transplantation. Donors of those renaltransplant recipients who were started on tacrolimus post-transplantation (n=53) were genotyped forMDR1 G2677T/A using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCRRFLP)analysis. Tacrolimus doses (mg/kg body weight), trough concentrations (ng/ml), dose-adjustedtrough concentrations (ng/ml per mg/kg body weight) were compared among patients according todonors’ allelic status for MDR1 (G2677T/A). Among the 53 donors, 28 (52.8%) were carriers of GG, 20(37.7%) of GT, and 5 (9.4%) of TT MDR1 alleles. Trough tacrolimus concentrations in recipients ofdonors carrying at least one T mutant alleles (2677TT or 2677GT, serine phenotype) did not differsignificantly from trough concentration in recipients of donors carrying homozygote wild, 2677GGgenotype (alanine) during the early 6 months post renal transplantation (P = 0.40, 0.62, 0.42, 0.60, 0.93,0.66 for months 1-6, respectively). In conclusion, donor’s MDR1 gene polymorphism has no impact ontrough tacrolimus concentration during the early period post-transplantation. To date, the results ofstudies remain controversial and many other factors must be considered to predict variability profile oftrough tacrolimus levels accurately.

کلیدواژه ها:

Tacrolimus ، dose requirements ، trough levels ، dose-adjusted trough concentrations